ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics total assets
Total assets on the balance sheet at the end of each period.
ProQR Therapeutics's total assets was €133.55M at Jun 30, 2026. For fiscal 2025 it was €112.76M, down 32.9% from the year before. The highest annual figure on record is €209.58M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €112.76M | -32.9% |
| FY2024 | Dec 31, 2024 | €167.96M | +21.8% |
| FY2023 | Dec 31, 2023 | €137.88M | -19.5% |
| FY2022 | Dec 31, 2022 | €171.32M | -18.3% |
| FY2021 | Dec 31, 2021 | €209.58M | +112.3% |
| FY2020 | Dec 31, 2020 | €98.73M | -16.0% |
| FY2019 | Dec 31, 2019 | €117.54M | +6.6% |
| FY2018 | Dec 31, 2018 | €110.23M | +107.6% |
| FY2017 | Dec 31, 2017 | €53.10M | -19.0% |
| FY2016 | Dec 31, 2016 | €65.54M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €133.55M | -2.9% |
| Q1 FY2026 | Mar 31, 2026 | €99.03M | -34.7% |
| Q4 FY2025 | Dec 31, 2025 | €112.76M | -32.9% |
| Q3 FY2025 | Sep 30, 2025 | €124.35M | +16.4% |
| Q2 FY2025 | Jun 30, 2025 | €137.54M | +16.5% |
| Q1 FY2025 | Mar 31, 2025 | €151.69M | +22.5% |
| Q4 FY2024 | Dec 31, 2024 | €167.96M | +21.8% |
| Q3 FY2024 | Sep 30, 2024 | €106.85M | -24.8% |
| Q2 FY2024 | Jun 30, 2024 | €118.05M | -20.2% |
| Q1 FY2024 | Mar 31, 2024 | €123.88M | -21.6% |
| Q4 FY2023 | Dec 31, 2023 | €137.88M | -19.5% |
| Q3 FY2023 | Sep 30, 2023 | €142.03M | +16.7% |
| Q2 FY2023 | Jun 30, 2023 | €147.99M | -17.3% |
| Q1 FY2023 | Mar 31, 2023 | €158.01M | -16.9% |
| Q4 FY2022 | Dec 31, 2022 | €171.32M | -18.3% |
| Q3 FY2022 | Sep 30, 2022 | €121.73M | -37.7% |
| Q2 FY2022 | Jun 30, 2022 | €179.05M | +10.3% |
| Q1 FY2022 | Mar 31, 2022 | €190.23M | +92.7% |
| Q4 FY2021 | Dec 31, 2021 | €209.58M | +90.2% |
| Q3 FY2021 | Sep 30, 2021 | €195.33M | +108.9% |
| Q2 FY2021 | Jun 30, 2021 | €162.36M | +56.7% |
| Q4 FY2020 | Dec 31, 2020 | €98.73M | -16.0% |
| Q3 FY2020 | Sep 30, 2020 | €110.19M | +35.9% |
| Q2 FY2020 | Jun 30, 2020 | €93.50M | +3.6% |
| Q1 FY2020 | Mar 31, 2020 | €103.63M | -6.0% |
| Q4 FY2019 | Dec 31, 2019 | €117.54M | +213.1% |
| Q3 FY2019 | Sep 30, 2019 | €81.06M | +52.7% |
| Q2 FY2019 | Jun 30, 2019 | €90.25M | +37.7% |
| Q4 FY2018 | Dec 31, 2018 | €110.23M | – |
| Q2 FY2018 | Jun 30, 2018 | €37.54M | – |
| Q4 FY2017 | Dec 31, 2017 | €53.10M | – |
| Q4 FY2016 | Dec 31, 2016 | €65.54M | – |
See a number that looks wrong?